Myriad Genetics Gives COO Options On 146,933 Shares With A Three-Year Service Requirement

The one-time retention awards also cover the finance and science chiefs as Myriad seeks better efficiency and financial performance.

Share
Myriad Genetics Gives COO Options On 146,933 Shares With A Three-Year Service Requirement

Myriad Genetics, which sells genetic tests to assess disease risk and guide treatment, approved executive retention options Friday, including 146,933 shares for Chief Operating Officer Mark S. Verratti. An SEC filing Monday sets out a service requirement: recipients must stay through the grant date's third anniversary before the options vest and can be exercised.

Verratti Gets The Largest Named Award

Verratti's grant is the largest among the named recipients. Chief Financial Officer Benjamin R. Wheeler received options on 121,379 shares, and Chief Scientific Officer Dale Muzzey received options on 92,632 shares.

Myriad's board compensation and human capital committee approved the one-time grants. The company said it wants to keep its leadership in place while pursuing initiatives to improve operating efficiency and financial performance.

Each option lets the recipient buy stock at the grant date's closing price. The awards have a ten-year term, although termination provisions can end them sooner.

Genetic Testing Across Cancer And Psychiatry

Myriad's business spans cancer testing, women's health and mental health. Its oncology tests include hereditary cancer, tumor and residual disease testing; its women's health offerings include prenatal and carrier screening. GeneSight helps clinicians select psychiatric medications.

The company serves patients, healthcare providers and biopharma partners, including through companion diagnostic development services. It sells mainly through its own sales force in the United States and Japan, with partnerships and indirect channels in Europe and Asia-Pacific.

Leaving Can End The Options

The recipients' existing severance and change-in-control agreements also govern how the retention options are treated when employment ends. Under the option agreement's general rules, vested options can be exercised for three months after departure, or until expiration if sooner, except for death, disability or dismissal for cause.

Dismissal for cause ends all unexercised options immediately, including vested ones. Death and disability provisions generally allow a one-year exercise window, bounded by the option's expiration date.

Myriad can also cancel the awards for breaches of confidentiality, non-solicitation, noncompetition or other restrictive obligations, subject to applicable law. A breach after shares have been delivered can require their return; if the shares were sold, the recipient must repay the pre-tax sale proceeds. These provisions extend to breaches after employment ends.

The options themselves carry no voting or dividend rights. Those rights begin only when shares obtained through exercise are registered in the recipient's name.

Sources

More on Myriad Genetics

All Myriad Genetics (MYGN) coverage →